Wealthstream Advisors Inc. Has $1.23 Million Stake in Eli Lilly and Company $LLY

Wealthstream Advisors Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 19.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,574 shares of the company’s stock after buying an additional 255 shares during the quarter. Wealthstream Advisors Inc.’s holdings in Eli Lilly and Company were worth $1,227,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd raised its holdings in Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after acquiring an additional 85 shares during the period. GAMMA Investing LLC raised its holdings in Eli Lilly and Company by 25.8% during the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock valued at $14,866,000 after acquiring an additional 3,696 shares during the period. Finally, Boston Trust Walden Corp raised its holdings in Eli Lilly and Company by 1.2% during the 1st quarter. Boston Trust Walden Corp now owns 3,284 shares of the company’s stock valued at $2,712,000 after acquiring an additional 40 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last three months. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LLY shares. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Finally, Leerink Partners reissued a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $939.12.

Eli Lilly and Company Trading Down 1.9%

Eli Lilly and Company stock opened at $803.53 on Friday. The stock has a market cap of $760.51 billion, a P/E ratio of 52.52, a PEG ratio of 1.15 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The firm’s fifty day moving average price is $753.09 and its 200-day moving average price is $765.86. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.